Atea Pharmaceuticals, Inc.
AVIR
$3.65
$0.1153.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 0.50% | -10.73% | -33.05% | -36.66% | -36.69% |
| Gross Profit | -0.50% | 10.73% | 33.05% | 36.66% | 36.69% |
| SG&A Expenses | -11.65% | -6.98% | -2.14% | -7.35% | -1.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.97% | -11.31% | 31.48% | 28.34% | 32.37% |
| Operating Income | 10.97% | 11.31% | -31.48% | -28.34% | -32.37% |
| Income Before Tax | 22.68% | 14.77% | -24.10% | -32.60% | -59.91% |
| Income Tax Expenses | -17.53% | -14.73% | -9.14% | 32.45% | 132.00% |
| Earnings from Continuing Operations | 22.65% | 14.77% | -23.85% | -32.60% | -65.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.65% | 14.77% | -23.85% | -32.60% | -65.80% |
| EBIT | 10.97% | 11.31% | -31.48% | -28.34% | -32.37% |
| EBITDA | 11.00% | 11.34% | -31.58% | -28.44% | -32.48% |
| EPS Basic | 23.25% | 15.73% | -22.67% | -31.63% | -64.91% |
| Normalized Basic EPS | 8.26% | 10.15% | -42.90% | -34.39% | -33.65% |
| EPS Diluted | 23.25% | 15.73% | -22.67% | -31.63% | -64.91% |
| Normalized Diluted EPS | 8.26% | 10.15% | -42.90% | -34.39% | -33.65% |
| Average Basic Shares Outstanding | 0.83% | 1.24% | 1.05% | 0.78% | 0.52% |
| Average Diluted Shares Outstanding | 0.83% | 1.24% | 1.05% | 0.78% | 0.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |